{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:51:14Z","timestamp":1790484674186,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK (GB)","doi-asserted-by":"crossref","award":["C490\/A16561"],"award-info":[{"award-number":["C490\/A16561"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12885-017-3585-x","type":"journal-article","created":{"date-parts":[[2017,9,20]],"date-time":"2017-09-20T07:22:55Z","timestamp":1505892175000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Association between tumour infiltrating lymphocytes, histotype and clinical outcome in epithelial ovarian cancer"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0824-6155","authenticated-orcid":false,"given":"Fiona R.","family":"James","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Jiminez-Linan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Alsop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Mack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Brenton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D. P.","family":"Pharoah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Raza","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,20]]},"reference":[{"issue":"2","key":"3585_CR1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","volume":"61","author":"A Jemal","year":"2011","unstructured":"Jemal A, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69\u201390.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"3585_CR2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/annonc\/mdi104","volume":"16","author":"R Agarwal","year":"2005","unstructured":"Agarwal R, Kaye SB. Prognostic factors in ovarian cancer: how close are we to a complete picture? Ann Oncol. 2005;16(1):4\u20136.","journal-title":"Ann Oncol"},{"issue":"7","key":"3585_CR3","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1200\/JCO.2009.27.2369","volume":"29","author":"LE Kandalaft","year":"2011","unstructured":"Kandalaft LE, et al. Immunotherapy for ovarian cancer: what's next? J Clin Oncol. 2011;29(7):925\u201333.","journal-title":"J Clin Oncol"},{"issue":"12","key":"3585_CR4","first-page":"4766","volume":"61","author":"EY Woo","year":"2001","unstructured":"Woo EY, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 2001;61(12):4766\u201372.","journal-title":"Cancer Res"},{"issue":"3","key":"3585_CR5","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","volume":"348","author":"L Zhang","year":"2003","unstructured":"Zhang L, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348(3):203\u201313.","journal-title":"N Engl J Med"},{"issue":"9","key":"3585_CR6","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm1093","volume":"10","author":"TJ Curiel","year":"2004","unstructured":"Curiel TJ, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10(9):942\u20139.","journal-title":"Nat Med"},{"issue":"51","key":"3585_CR7","doi-asserted-by":"crossref","first-page":"18538","DOI":"10.1073\/pnas.0509182102","volume":"102","author":"E Sato","year":"2005","unstructured":"Sato E, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+\/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005;102(51):18538\u201343.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"3585_CR8","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0611533104","volume":"104","author":"J Hamanishi","year":"2007","unstructured":"Hamanishi J, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A. 2007;104(9):3360\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"3585_CR9","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ygyno.2007.10.016","volume":"108","author":"M Tomsova","year":"2008","unstructured":"Tomsova M, et al. Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma. Gynecol Oncol. 2008;108(2):415\u201320.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"3585_CR10","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ygyno.2008.01.010","volume":"109","author":"CA Shah","year":"2008","unstructured":"Shah CA, et al. Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer. Gynecol Oncol. 2008;109(2):215\u20139.","journal-title":"Gynecol Oncol"},{"issue":"13","key":"3585_CR11","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1002\/cncr.24317","volume":"115","author":"SF Adams","year":"2009","unstructured":"Adams SF, et al. Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer. Cancer. 2009;115(13):2891\u2013902.","journal-title":"Cancer"},{"issue":"3","key":"3585_CR12","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/modpathol.2008.191","volume":"22","author":"B Clarke","year":"2009","unstructured":"Clarke B, et al. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol. 2009;22(3):393\u2013402.","journal-title":"Mod Pathol"},{"issue":"3","key":"3585_CR13","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00262-008-0583-5","volume":"58","author":"N Leffers","year":"2009","unstructured":"Leffers N, et al. Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother. 2009;58(3):449\u201359.","journal-title":"Cancer Immunol Immunother"},{"issue":"9","key":"3585_CR14","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1038\/sj.bjc.6605274","volume":"101","author":"M Stumpf","year":"2009","unstructured":"Stumpf M, et al. Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: relevance of clonal selection of T lymphocytes. Br J Cancer. 2009;101(9):1513\u201321.","journal-title":"Br J Cancer"},{"issue":"2","key":"3585_CR15","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ygyno.2016.03.008","volume":"141","author":"JR Webb","year":"2016","unstructured":"Webb JR, et al. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. Gynecol Oncol. 2016 May;141(2):293\u2013302.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"3585_CR16","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.18632\/oncotarget.6429","volume":"7","author":"S Darb-Esfahani","year":"2016","unstructured":"Darb-Esfahani S, et al. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma. Oncotarget. 2016 Jan 12;7(2):1486\u201399.","journal-title":"Oncotarget"},{"issue":"5","key":"3585_CR17","doi-asserted-by":"crossref","first-page":"e1122863","DOI":"10.1080\/2162402X.2015.1122863","volume":"5","author":"MC Woulters","year":"2016","unstructured":"Woulters MC, et al. Size matters: survival benefit conferred by intratumoral T cells is dependent on surgical outcome, treatment sequence and T cell differentiation. Oncoimmunology. 2016 Jan 4;5(5):e1122863.","journal-title":"Oncoimmunology"},{"issue":"4","key":"3585_CR18","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1097\/IGC.0000000000000672","volume":"26","author":"HC B\u00f6sm\u00fcller","year":"2016","unstructured":"B\u00f6sm\u00fcller HC, et al. Combined Immunoscore of CD103 and CD3 identifies long-term survivors in high-grade serous ovarian cancer. Int J Gynecol Cancer. 2016 May;26(4):671\u20139.","journal-title":"Int J Gynecol Cancer"},{"issue":"12","key":"3585_CR19","doi-asserted-by":"crossref","first-page":"13587","DOI":"10.18632\/oncotarget.7277","volume":"7","author":"KC Strickland","year":"2016","unstructured":"Strickland KC, et al. Association and prognostic significance of BRCA1\/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1\/PD-L1 in high grade serous ovarian cancer. Oncotarget. 2016 Mar 22;7(12):13587\u201398.","journal-title":"Oncotarget"},{"issue":"12","key":"3585_CR20","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1158\/1078-0432.CCR-15-2762","volume":"22","author":"DR Kroeger","year":"2016","unstructured":"Kroeger DR, et al. Tumor-infiltrating plasma cells are associated with tertiary lymphoid structures, Cytolytic T-cell responses, and superior prognosis in ovarian cancer. Clin Cancer Res. 2016 Jun 15;22(12):3005\u201315.","journal-title":"Clin Cancer Res"},{"issue":"16","key":"3585_CR21","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-08-0196","volume":"14","author":"RW Tothill","year":"2008","unstructured":"Tothill RW, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008;14(16):5198\u2013208.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"3585_CR22","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/path.4287","volume":"232","author":"J Galon","year":"2014","unstructured":"Galon J, et al. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol. 2014;232(2):199\u2013209.","journal-title":"J Pathol"},{"issue":"2","key":"3585_CR23","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/annonc\/mdu450","volume":"26","author":"R Salgado","year":"2015","unstructured":"Salgado R, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs working group 2014. Ann Oncol. 2015;26(2):259\u201371.","journal-title":"Ann Oncol"},{"issue":"11","key":"3585_CR24","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1093\/carcin\/bgl089","volume":"27","author":"H Song","year":"2006","unstructured":"Song H, et al. Common variants in mismatch repair genes and risk of invasive ovarian cancer. Carcinogenesis. 2006;27(11):2235\u201342.","journal-title":"Carcinogenesis"},{"issue":"11","key":"3585_CR25","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1038\/sj.bjc.6605062","volume":"100","author":"EM Azzato","year":"2009","unstructured":"Azzato EM, et al. Prevalent cases in observational studies of cancer survival: do they bias hazard ratio estimates? Br J Cancer. 2009;100(11):1806\u201311.","journal-title":"Br J Cancer"},{"issue":"6230","key":"3585_CR26","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1126\/science.aaa6204","volume":"348","author":"JA Joyce","year":"2015","unstructured":"Joyce JA, et al. T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015. Apr 3;348(6230):74\u201380.","journal-title":"Science"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-017-3585-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,9,20]],"date-time":"2017-09-20T07:23:08Z","timestamp":1505892188000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-017-3585-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,20]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["3585"],"URL":"https:\/\/doi.org\/10.1186\/s12885-017-3585-x","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,20]]},"article-number":"657"}}